Dan Gilad

Armenta

Armenta Ltd., an Agtech company, is developing innovative therapies to transform the standard of care for dairy cattle diseases. Our first target indication, mastitis, is a significant economic burden on dairy farms. It reduces milk yield and quality and increases culling rates, causing more than $2B in lost annual revenue in the U.S. and more than $1.5B in the E.U. Armenta aims to dramatically reduce the monetary losses from these pathologies, with the focus on a non-antibiotic mastitis therapy.